Lupin shares fall despite 55% rise in Q1 net profit

Pharmaceutical major Lupin, on Tuesday, reported consolidated net profit of Rs 881.9 crore, registering growth of 55.12% yoy (year-on-year) and 17.93% qoq (quarter-on-quarter) for the quarter ended June 30, 2016.

Commenting on the results, Nilesh Gupta, Managing Director, Lupin Limited, said “This was a record quarter, driven by robust growth across all our key markets – the United States, India and Japan. We remain committed to maintaining our growth trajectory given new product launches and approvals driven by strategic investments in technology and research.”  

It’s consolidated total income stood at Rs 4439.4 crore, which witnessed rise of 40.66% yoy and 6.44% qoq. While consolidated operating profit (EBITDA – earnings before interest tax depreciation and amortization) was at Rs 1308 crore, increasing by 58.60% yoy and 0.23% qoq. 

Further the company's operating profit margin (OPM) was around 29.46%, expanding by 333 basis points yoy. However, it did contracted by 182 basis points against the preceding quarter. 

The company's standalone operating profit also performed positively, with Rs 1536.5 crore during June quarter, growing by 66.41% yoy and 14.76% qoq. It's OPM was at 43.26%, expanding by 767 basis points yoy and 210 basis points qoq. 

In regards to international sales, the company's US formulation sales increased by 78.9% to USD 322 million in Q1 FY2017 over corresponding period of the previous year. Also Japan unit, recorded sales of Rs 4232 million which grew by 30.9% yoy. 

The share price of Lupin slumped despite strong Q1FY17. The stocks were trading at Rs 1639 down by Rs 53.75 or 3.18%.

The following graph states the market performance of Lupin declining right after its Q1FY17 results announcement.